Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Decitabine in Unfit AML
NCT03395873Phase 1Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab in acute myeloid leukemia (AML), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Safety of Avelumab in combination with decitabine at 28 days. Started Jan 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03395873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395873.